Teduglutide
/ Recombinant analog of GLP-2; selective GLP-2 receptor agonistALIAS · Gattex · Revestive
Terms in this page you can click for a plain-English popup: , , , , , , , .
FDA-approved (Gattex, 2012) for short bowel syndrome in adults and pediatric patients requiring parenteral nutrition support. The only approved GLP-2 analog.
Teduglutide is a 33-amino-acid recombinant analog of glucagon-like peptide-2 (GLP-2), modified at position 2 (Ala-to-Gly substitution) to resist DPP-4 degradation. It stimulates intestinal growth and absorption through the GLP-2 receptor, enlarging villus height and crypt depth and reducing parenteral nutrition requirements in short bowel syndrome.
Registrational STEPS trials in adults with short bowel syndrome supported FDA approval. Reduces parenteral support volume in approximately 60% of treated patients.
Warnings and precautions include intestinal neoplasia (colonoscopy monitoring required), bowel obstruction, biliary and pancreatic disease (colon polyps, cholecystitis, pancreatitis), and fluid overload. Injection-site reactions are common.
Regulatory status
- FDA status:
- FDA-approved
- Compounding:
- Not eligible for compounding (approved, not in shortage)